{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:08:25Z","timestamp":1791976105553,"version":"4.4.0"},"reference-count":46,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2009,2,4]],"date-time":"2009-02-04T00:00:00Z","timestamp":1233705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2009,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Dasatinib is a highly potent Bcr\u2010Abl inhibitor that is approved for the treatment of imatinib\u2010resistant or \u2010intolerant chronic myeloid leukemia (CML) and Philadelphia chromosome\u2010positive acute lymphoblastic leukemia. Across a series of phase 2 and 3 trials, dasatinib was associated with durable treatment responses in all phases of the disease and was well tolerated. For this article, the authors reviewed available information on specific side effects associated with the use of dasatinib. On the basis of more than 2 years' experience of dasatinib treatment during clinical trials, they provide practical recommendations for side\u2010effect management. Cancer 2009. \u00a9 2009 American Cancer Society.<\/jats:p>","DOI":"10.1002\/cncr.24155","type":"journal-article","created":{"date-parts":[[2009,2,4]],"date-time":"2009-02-04T21:59:36Z","timestamp":1233784776000},"page":"1381-1394","source":"Crossref","is-referenced-by-count":46,"title":["Dasatinib treatment for Philadelphia chromosome\u2010positive leukemias"],"prefix":"10.1002","volume":"115","author":[{"given":"Hanna Jean","family":"Khoury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Guilhot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong\u2010Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,2,4]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199904293401706"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2007.1.435"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2004.03.011"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3097"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.6.1928"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3530"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4187"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0259"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4175"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055229"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-047266"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-046839"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-046888"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-073528"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-056028"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.84"},{"key":"e_1_2_5_19_2","doi-asserted-by":"crossref","first-page":"613a","DOI":"10.1182\/blood.V108.11.2160.2160","article-title":"Dasatinib (SPRYCEL\u00ae) in patients with chronic myelogenous leukemia in accelerated phase that is imatinib\u2010resistant or \u2010intolerant: updated results of the CA180\u2010005 \u2018START\u2010A\u2019 phase II study [abstract]","volume":"108","author":"Cortes J","year":"2006","journal-title":"Blood."},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.221"},{"issue":"1","key":"e_1_2_5_21_2","first-page":"9","article-title":"Dasatinib induces rapid and durable responses in patients with Ph+ ALL resistant or intolerant to imatinib: updated results from CA180015 (START\u2010L) trial [abstract]","volume":"92","author":"Ottmann O","year":"2007","journal-title":"Haematologica."},{"issue":"1","key":"e_1_2_5_22_2","first-page":"128","article-title":"Dasatinib dose and schedule optimization in chronic\u2010phase CML resistant or intolerant to imatinib: results from a randomized phase\u2010III trial (CA180034) [abstract]","volume":"92","author":"Hochhaus A","year":"2007","journal-title":"Haematologica."},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.9260"},{"key":"e_1_2_5_24_2","volume-title":"SPRYCEL\u00ae prescribing information (US)","author":"Bristol\u2010Myers Squibb","year":"2007"},{"key":"e_1_2_5_25_2","volume-title":"SPRYCEL\u00ae summary of product characteristics (EU)","author":"Bristol\u2010Myers Squibb","year":"2007"},{"issue":"1","key":"e_1_2_5_26_2","first-page":"319","article-title":"Dasatinib 140 mg QD vs 70 mg bid in advanced\u2010phase CML or Ph(+) ALL resistant or intolerant to imatinib: results from a randomized, phase\u2010III trial (CA180035) [abstract]","volume":"92","author":"Dombret H","year":"2007","journal-title":"Haematologica."},{"key":"e_1_2_5_27_2","doi-asserted-by":"crossref","first-page":"225a","DOI":"10.1182\/blood.V110.11.734.734","article-title":"Efficacy of dasatinib in patients with chronic\u2010phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2\u2010year follow\u2010up data from START\u2010C (CA180\u2010013) [abstract]","volume":"110","author":"Stone RM","year":"2007","journal-title":"Blood."},{"key":"e_1_2_5_28_2","doi-asserted-by":"crossref","first-page":"145a","DOI":"10.1182\/blood.V110.11.470.470","article-title":"Efficacy of dasatinib in patients with accelerated\u2010phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2\u2010year follow\u2010up data from START\u2010A (CA180\u2010005) [abstract]","volume":"110","author":"Guilhot F","year":"2007","journal-title":"Blood."},{"key":"e_1_2_5_29_2","doi-asserted-by":"crossref","first-page":"145a","DOI":"10.1182\/blood.V110.11.472.472","article-title":"Efficacy and safety of dasatinib in patients with chronic myeloid leukemia in blast phase whose disease is resistant or intolerant to imatinib: 2\u2010year follow\u2010up data from the START program [abstract]","volume":"110","author":"Gambacorti C","year":"2007","journal-title":"Blood."},{"key":"e_1_2_5_30_2","doi-asserted-by":"crossref","first-page":"826a","DOI":"10.1182\/blood.V110.11.2810.2810","article-title":"Efficacy of dasatinib in patients with Philadelphia\u2010chromosome\u2010positive acute lymphoblastic leukemia who are resistant or intolerant to imatinib: 2\u2010year follow\u2010up data from START\u2010L (CA180\u2010015) [abstract]","volume":"110","author":"Porkka K","year":"2007","journal-title":"Blood."},{"key":"e_1_2_5_31_2","doi-asserted-by":"crossref","first-page":"375s","DOI":"10.1200\/jco.2008.26.15_suppl.7015","article-title":"Dasatinib lack of cross intolerance to imatinib in patients (pts) with chronic myelogenous leukemia chronic phase (CMLCP) intolerant to imatinib: a retrospective analysis of safety [abstract]","volume":"26","author":"Khoury HJ","year":"2008","journal-title":"J Clin Oncol."},{"key":"e_1_2_5_32_2","doi-asserted-by":"crossref","first-page":"613a","DOI":"10.1182\/blood.V108.11.2163.2163","article-title":"Cytopenias in patients with chronic myelogenous leukemia in chronic phase treated with dasatinib (SPRYCEL\u00ae): clinical features and management, including outcome after hematopoietic growth factor therapy [abstract]","volume":"108","author":"Quintas\u2010Cardama A","year":"2006","journal-title":"Blood."},{"key":"e_1_2_5_33_2","unstructured":"National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia version 3.2008. Available athttp:\/\/www.nccn.org\/ professionals\/physician_gls\/PDF\/cml.pdf. Accessed January 2009."},{"key":"e_1_2_5_34_2","doi-asserted-by":"crossref","first-page":"869a","DOI":"10.1182\/blood.V110.11.2958.2958","article-title":"Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy [abstract]","volume":"110","author":"Quintas\u2010Cardama A","year":"2007","journal-title":"Blood."},{"key":"e_1_2_5_35_2","doi-asserted-by":"crossref","first-page":"864a","DOI":"10.1182\/blood.V110.11.2941.2941","article-title":"Dasatinib\u2010induced platelet dysfunction [abstract]","volume":"110","author":"Quintas\u2010Cardama A","year":"2007","journal-title":"Blood."},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.0329"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07108.x"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.4065\/81.9.1241"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.032"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1366"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.11.9.1207"},{"key":"e_1_2_5_42_2","doi-asserted-by":"crossref","first-page":"146a","DOI":"10.1182\/blood.V110.11.473.473","article-title":"Bosutinib (SKI\u2010606) demonstrates clinical activity and is well tolerated among patients with AP and BP CML and Ph+ ALL [abstract]","volume":"110","author":"Gambacorti\u2010Passerini C","year":"2007","journal-title":"Blood."},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200705-715CR"},{"key":"e_1_2_5_44_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.143"},{"key":"e_1_2_5_45_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_2_5_46_2","doi-asserted-by":"crossref","first-page":"318a","DOI":"10.1182\/blood.V110.11.1049.1049","article-title":"Dasatinib (SPRYCEL\u00ae) in children and adolescents with relapsed or refractory leukemia: preliminary results of the CA180018 phase I\/II study from the ITCC Consortium [abstract]","volume":"110","author":"Zwaan CM","year":"2007","journal-title":"Blood."},{"key":"e_1_2_5_47_2","doi-asserted-by":"crossref","first-page":"175s","DOI":"10.1200\/jco.2008.26.15_suppl.3591","article-title":"Pediatric phase I trial and pharmacokinetic (PK) study of dasatinib: a report from the Children's Oncology Group Phase I Consortium [abstract]","volume":"26","author":"Aplenc R","year":"2008","journal-title":"J Clin Oncol."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.24155","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.24155","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:55:04Z","timestamp":1760298904000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.24155"}},"subtitle":["Practical considerations"],"short-title":[],"issued":{"date-parts":[[2009,2,4]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["10.1002\/cncr.24155"],"URL":"https:\/\/doi.org\/10.1002\/cncr.24155","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,4]]}}}